Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20494591 | 1.00 | PDE2A (0.35) | PDE2APDK2L3MBTL1MGLLS1PR3 | |
| SCHEMBL30027153 | 1.00 | PDE2A (0.35) | PDE2APDK2L3MBTL1MGLLS1PR3 | |
| SCHEMBL14321311 | 0.81 | TP53 (0.47) | PDE2APDK2LMNATP53HTT | |
| SCHEMBL1343758 | 0.79 | APLNR (0.36) | PDE2A | |
| SCHEMBL14321599 | 0.79 | TSHR (0.41) | PDE2APDK2MGLLGAALMNA | |
| SCHEMBL22852524 | 0.78 | ALDH1A1 (0.44) | PDE2APDK2MGLLGAALMNA | |
| SCHEMBL22836962 | 0.78 | ALDH1A1 (0.44) | PDE2APDK2MGLLGAALMNA | |
| SCHEMBL18057575 | 0.78 | MGLL (0.48) | PDE2APDK2MGLLGAALMNA | |
| SCHEMBL18043683 | 0.78 | GAA (0.37) | PDE2APDK2MGLLGAALMNA | |
| SCHEMBL613152 | 0.78 | GAA (0.37) | PDE2APDK2MGLLGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| CN-111315746-B | Tryptophan hydroxylase inhibitors and pharmaceutical compositions comprising the same | 光州科学技术院 | 2022-11-29 | — | — | CN | disclosed |
| US-11407763-B2 | Tryptophan hydroxylase inhibitor and pharmaceutical composition including same | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLGY (KR) | 2022-08-09 | — | — | US | disclosed |
| EP-3674303-B1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | GWANGJU INST SCIENCE & TECH (KR) | 2022-07-20 | — | — | EP | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-20210155634-A1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2021-05-27 | — | — | US | disclosed |
| EP-3808740-A1 | ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | TerSera Therapeutics LLC (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2010065333-A1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS | LEXICON PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-7709493-B2 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-2178536-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | Lexicon Pharmaceuticals, Inc. (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090286817-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | TERSERA THERAPEUTICS LLC | 2009-11-19 | — | — | US | disclosed |
| EP-2091940-A2 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7553840-B2 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | LEXICON PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2009014972-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20080153852-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | TERSERA THERAPEUTICS LLC | 2008-06-26 | — | — | US | disclosed |
| WO-2008073933-A2 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286817-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | TPH1, TPH2, PAH | PDE2A 1583/4885PDK2 356/4885L3MBTL1 2400/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | PDE2A 3073/4885PDK2 802/4885L3MBTL1 1960/4885 |
| US-11407763-B2 | Tryptophan hydroxylase inhibitor and pharmaceutical composition including same | TPH1, TPH2, IDO1 | PDE2A 1690/4885PDK2 715/4885L3MBTL1 4374/4885 |
| US-20080153852-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | TPH1, TPH2, MAOA | PDE2A 1264/4885PDK2 745/4885L3MBTL1 3182/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | PDE2A 3073/4885PDK2 802/4885L3MBTL1 1960/4885 |
| US-20210155634-A1 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | TPH1, TPH2, IDO1 | PDE2A 1515/4885PDK2 767/4885L3MBTL1 4359/4885 |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | TPH1, TPH2, HNMT | PDE2A 224/4885PDK2 1577/4885L3MBTL1 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.